

Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Ascierto PA, Del Vecchio M, Mackiewicz A, *et al.* Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. *J Immunother Cancer* 2020;8:e000391. doi: 10.1136/jitc-2019-000391

Since the online publication of this article, it was noticed that 'Michele Del Vecchio' was incorrectly spelt as 'Michelle Del Vecchio'. This error has been corrected.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

J Immunother Cancer 2020;8:e000391corr1. doi:10.1136/jitc-2019-000391corr1

